Previous 10 | Next 10 |
home / stock / bivi / bivi articles
Recently completed financing provides sufficient funds for near-term Parkinson's Disease priority Plans for Phase 2b trial of NE3107 as first...
NEW YORK, March 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds inves...
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioVie Inc. ("BioVie" or the "Company...
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons an...
NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioVi...
NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioVie Inc. ("BioVie" or the "Company...
U.S. stocks traded lower toward the end of trading, with the S&P 500 edging lower on Monday. The Dow traded down 0.20% to 39,007.30 while the N...
Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quar...
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 0.2% on Monday. The Dow traded down 0.25% to 38,988.86 wh...
News, Short Squeeze, Breakout and More Instantly...
SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson’s disease who are naïve to carbidopa/levodopa Additional presentation at congress highlighted data from earlier Phase 2a trial of bezisterim in Parkinson...
ORLANDO, FL / ACCESSWIRE / June 21, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Mobilicom Ltd. (Nasdaq:MOB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 22, at 7 p.m. Eastern Time (ET). Bloomb...
CARSON CITY, Nev., June 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, ...